全细胞医护科技 OMCL 深 沪
等待开盘 04-01 09:30:00 美东时间
33.38
+1.030
+3.18%
华盛通- 最 高33.52
- 今 开32.82
- 成交量 97.67万股
- 最 低 31.75
- 昨 收 32.35
- 总市值 15.17亿
- 52周最高 55.00
- 市盈率 静 753.50
- 换手率 2.15%
- 52周最低 22.66
- 委 比 -98.46%
- 总股本 4543.59万
- 历史最高 187.285
- 量 比 2.26
- 振 幅 5.47%
- 历史最低 12.33
- 每 手 1
- 风险率 6.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多新浪财经ESG：Omnicell MSCI（明晟）ESG评级调升至AAA
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:27
新浪财经ESG：Omnicell MSCI（明晟）ESG评级调升至AA
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-14 07:00
Omnicell EVP and Chief Legal/Admin Officer Corey J. Manley Disposes of Common Shares
Omnicell EVP and Chief Legal/Admin Officer Corey J. Manley Disposes of Common Shares Corey J. Manley, EVP & Chief Legal/Admin Officer of Omnicell, Inc., reported a disposal of common shares of Omnicell, Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was crea
02-19 05:06
美股大行评级 | 遭多家大行下调目标价！亚马逊、Affirm、Roblox、汤森路透、Doximity、OneMain、Atlassian、Peloton等等
今日重点评级关注：HC Wainwright & Co.：维持NovaBridge Biosciences"买入"评级，目标价从7美元升至9美元；Truist Securities：维持Reddit"买入"评级，目标价从270美元升至275美元
02-09 14:37
U.S. RESEARCH ROUNDUP-Amazon, Estée Lauder, Ralph Lauren
U.S. RESEARCH ROUNDUP-Amazon, Estée Lauder, Ralph Lauren Feb 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, Estée Lauder and Ralph Lauren, on Friday. HIGHLIGHTS * Amazon AMZN.O : HSBC cuts target price to $280
02-06 14:52
Omnicell shares are trading lower after the company reported mixed Q4 financial results and issued FY26 adjusted EPS guidance below estimates.
Omnicell shares are trading lower after the company reported mixed Q4 financial...
02-05 22:19
Omnicell veröffentlicht Präsentation zur Strategie für automatisiertes Medikamentenmanagement und Wachstum
Omnicell veröffentlicht Präsentation zur Strategie für automatisiertes Medikamentenmanagement und Wachstum Omnicell Inc. hat eine neue Präsentation veröffentlicht, in der das Unternehmen seine aktuellen Strategien und Innovationen im Bereich der Automatisierung und Digitalisierung der Medikamentenve
02-05 19:55
Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Recurring Revenue Growth
Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Recurring Revenue Growth Omnicell Inc. has released an investor presentation outlining its strategy to drive growth in the healthcare technology sector. The company highlighted its position as a leader in medication management
02-05 19:55
Omnicell Q4 EPS misses estimates
Omnicell Q4 EPS misses estimates Overview Healthcare technology provider's fiscal Q4 revenue grew 2% yr/yr Adjusted EPS for fiscal Q4 missed analyst expectations Company launched Titan XT dispensing system to enhance medication management Outlook Omnicell projects 2026 total revenues between $1.215
02-05 19:39
Omnicell Sees Q1 2026 Adj EPS $0.26-$0.36 vs $0.29 Est; Sees Sales $300.000M-$310.000M vs $281.484M Est
2026 GuidanceThe table below summarizes Omnicell's first quarter and full year 2026 guidance: Q1 2026 2026Product BookingsNot provided $510 million - $560 millionAnnual Recurring RevenueNot
02-05 19:33
